



Acutus Medical® Announces Completion of Enrollment for UNCOVER AF™ Study of AcQMap® in Persistent Atrial Fibrillation

CARLSBAD, CA, April 27, 2017—Acutus Medical®, a company committed to transforming the lives of millions of patients with complex arrhythmias, today announced that enrollment has been completed in its pivotal **U**tilizing **N**ovel Dipole Density **C**apabilities to **O**bjectively **V**isualize the **E**tiology of **R**hythms in **A**trial **F**ibrillation (UNCOVER AF™) study evaluating the AcQMap® High Resolution Imaging and Mapping System in patients with persistent atrial fibrillation (AF) in Europe and Canada.

The UNCOVER AF clinical study is a prospective, multi-center, multi-national study designed to provide clinical evidence regarding the use of the AcQMap® System in the treatment of persistent AF. The trial is being conducted at 13 sites throughout Europe and Canada and has successfully completed enrollment of 129 patients.

“We are encouraged by the rate at which we were able to enroll this study and the outcomes thus far”, said Randy Werneth, President and Chief Executive Officer of Acutus. “We believe strongly in AcQMap’s ability to address critical unmet needs in mapping AF. AcQMap enables patient specific diagnosis, treatment guidance and confirmation of the delivered treatment that is intended to greatly benefit millions of patients who, until now, face a 50/50 chance of a successful outcome after an initial ablation procedure.”

Acutus received CE Mark approval for AcQMap in May 2016 and is currently pursuing U.S. FDA clearance for the system.

About AcQMap High Resolution Imaging and Mapping System

The Acutus AcQMap High Resolution Imaging and Mapping System, our diagnostic platform, is a technology that reveals the electrical conduction of the whole heart chamber along with the heart wall motion (functional structure). The AcQMap System utilizes the unique combination of ultrasound to create a CT quality anatomy and non-contact, dipole density propagation maps to visualize previously unmappable complex arrhythmias (AF, Atypical Flutter) without the confounding effects of far field signals. This allows physicians for the first time to see real-time electrical activity within the heart chamber, with the ability to remap in seconds to confirm successful substrate modification via ablation therapy.

Additionally, the company is developing a significantly differentiated ablation technology designed to provide functionality that will further advance and support an electrophysiologist’s desire to produce improved, durable, patient-specific benefits.

About Acutus Medical

Acutus Medical is a company committed to transforming the lives of millions of patients by providing electrophysiologists a highly unique, dual-platform portfolio of breakthrough products that image, diagnose and treat complex arrhythmias. Acutus is pioneering ElectroFunctional™



procedures, that provide electrophysiologists a unique ability to establish and execute highly informed, patient-specific treatment strategies for complex cardiac arrhythmias.

Acutus Medical is a privately held company located in Carlsbad, CA. To learn more, visit <http://www.acutusmedical.com>

The AcQMap High Resolution Imaging and Mapping System is not available for sale in the United States.

###

Media Contact

Julia Baron

Pure Communications

+ 1 (415) 658-9766

jbaron@purecommunications.com

Investor Contact

Matt Clawson

Pure Communications, Inc.

+1 (949) 370-8500

matt@purecommunicationsinc.com